Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16311051 | 0.83 | CA12 (0.58) | CYP2C19CA12CA7CA9CA14 | |
| SCHEMBL12305030 | 0.77 | CYP2C19 (0.44) | CYP2C19KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL28291990 | 0.76 | CA1 (0.47) | CYP2C19CA9KMT2AALDH1A1MEN1 | |
| SCHEMBL4891867 | 0.75 | APAF1 (0.53) | CYP2C19CA12CA7CA9CA14 | |
| SCHEMBL3207687 | 0.75 | CA12 (0.49) | CYP2C19CA12CA7CA9CA14 | |
| SCHEMBL11445835 | 0.72 | CYP2C19 (0.54) | CYP2C19FFAR1ALDH1A1MAPT | |
| SCHEMBL29323684 | 0.72 | THRB (0.49) | CYP2C19CA12CA7CA9CA14 | |
| SCHEMBL1200575 | 0.72 | APEX1 (0.52) | APEX1KMT2AALDH1A1HTTNPSR1 | |
| SCHEMBL13037424 | 0.71 | BRD4 (0.42) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL4170789 | 0.70 | MMP12 (0.46) | CYP2C19CA12CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045518-B2 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040267022-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. | 2004-12-30 | — | — | US | disclosed |
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0813519-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5482947-A | ENZYME INHIBITORS FOR HIV PROTEASE INHIBITION FROM UREA OR THIOUREA COMPOUNDS | TALLEY JOHN J (US) | 1996-01-09 | — | — | US | disclosed |
| EP-0666843-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0656888-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267022-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, PRSS1, TMPRSS15 | CYP2C19 3580/4885CA12 2552/4885CA7 2546/4885 |
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | CYP2C19 3273/4885CA12 3262/4885CA7 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.